Market Research Logo

Global Transdermal Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts

Global Transdermal Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts
Transdermal Drug Delivery Partnering 2012-2018 report provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.

Trends in transdermal drug delivery partnering deals
Top transdermal drug delivery deals by value
Deals listed by company A-Z, deal type, stage of development, therapy type

This report provides details of the latest Transdermal Drug Delivery agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Transdermal Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Transdermal Drug Delivery partnering deals.

The report presents financial deal term values for Transdermal Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Transdermal Drug Delivery partnering field; both the leading deal values and most active Transdermal Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 150 online deal records of actual Transdermal Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Transdermal Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Transdermal Drug Delivery dealmaking since 2012, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Transdermal Drug Delivery deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Transdermal Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Transdermal Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Transdermal Drug Delivery partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Transdermal Drug Delivery partnering deals signed and announced since Jan 2012. The chapter is organized by specific Transdermal Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Transdermal Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Transdermal Drug Delivery partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Transdermal Drug Delivery technologies and products.

Key benefits

Global Transdermal Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Transdermal Drug Delivery deal trends since 2012
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Transdermal Drug Delivery agreements with numerous real life case studies
Detailed access to actual Transdermal Drug Delivery contracts entered into by leading biopharma companies
Identify most active Transdermal Drug Delivery dealmakers since 2012
Insight into terms included in a Transdermal Drug Delivery partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Transdermal Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Transdermal Drug Delivery trends and structure of deals entered into by leading companies worldwide.

Transdermal Drug Delivery Partnering Terms and Agreements includes:

Trends in Transdermal Drug Delivery dealmaking in the biopharma industry since 2012
Analysis of Transdermal Drug Delivery deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Transdermal Drug Delivery deals
Access to Transdermal Drug Delivery contract documents
Leading Transdermal Drug Delivery deals by value since 2012
Most active Transdermal Drug Delivery dealmakers since 2012

In Global Transdermal Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Transdermal Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 150 Transdermal Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?


Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Transdermal Drug Delivery dealmaking
2.1. Introduction
2.2. Transdermal Drug Delivery partnering over the years
2.3. Most active Transdermal Drug Delivery dealmakers
2.4. Transdermal Drug Delivery partnering by deal type
2.5. Transdermal Drug Delivery partnering by therapy area
2.6. Deal terms for Transdermal Drug Delivery partnering
2.6.1 Transdermal Drug Delivery partnering headline values
2.6.2 Transdermal Drug Delivery deal upfront payments7
2.6.3 Transdermal Drug Delivery deal milestone payments
2.6.4 Transdermal Drug Delivery royalty rates
Chapter 3 – Leading Transdermal Drug Delivery deals
3.1. Introduction
3.2. Top Transdermal Drug Delivery deals by value
Chapter 4 – Most active Transdermal Drug Delivery dealmakers
4.1. Introduction
4.2. Most active Transdermal Drug Delivery dealmakers
4.3. Most active Transdermal Drug Delivery partnering company profiles
Chapter 5 – Transdermal Drug Delivery contracts dealmaking directory
5.1. Introduction
5.2. Transdermal Drug Delivery contracts dealmaking directory
Chapter 6 – Transdermal Drug Delivery dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Transdermal Drug Delivery deals by company A-Z
Appendix 2 – Transdermal Drug Delivery deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 – Transdermal Drug Delivery deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 – Transdermal Drug Delivery deals by therapy area
Appendix 5 –Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Transdermal Drug Delivery partnering since 2012
Figure 2: Active Transdermal Drug Delivery dealmaking activity– 2012 to 2018
Figure 3: Transdermal Drug Delivery partnering by deal type since 2012
Figure 4: Transdermal Drug Delivery partnering by disease type since 2012
Figure 5: Transdermal Drug Delivery deals with a headline value
Figure 6: Transdermal Drug Delivery deals with an upfront value
Figure 7: Transdermal Drug Delivery deals with a milestone value
Figure 8: Transdermal Drug Delivery deals with a royalty rate value
Figure 9: Top Transdermal Drug Delivery deals by value since 2012
Figure 10: Most active Transdermal Drug Delivery dealmakers 2012 to 2018
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report